ArticleJournal of gastrointestinal cancer2025
Bioinformatics Analysis Reveals the Role of DLGAP4 in the Development and Progression of Hepatocellular Carcinoma.
Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeAlthough the DLGAP4 gene is well-established in neurological disorders, its function in hepatocellular carcinoma (HCC) remains unclear. This study aims to characterize DLGAP4 expression patterns, prognostic significance, and association with immune infiltration in the HCC tumor microenvironment, to assess its potential as a biomarker or therapeutic target.
methodsWe analyzed DLGAP4 expression in HCC and its prognostic significance using the TCGA database, performing survival analysis with the Kaplan-Meier method. Functional pathways linked to DLGAP4 were identified via GO and KEGG enrichment analyses, and further explored by gene set variation analysis (GSVA). Immune cell infiltration correlations were assessed using TIMER2.0. Clinical samples were immunohistochemically stained to validate bioinformatic results.
resultsDLGAP4 expression was significantly upregulated in HCC tissues and associated with poor patient prognosis. Enrichment analysis implicated DLGAP4 in biological processes including chromatin modification and protein translation. Single-cell data analysis revealed that high DLGAP4 expression correlated with features of the tumor microenvironment, such as tumor-associated macrophages, stemness, angiogenesis, and metabolic reprogramming. Immunohistochemical results further confirmed a significant correlation between DLGAP4 expression and immune cell infiltration.
conclusionsDLGAP4 is upregulated in HCC and associated with poor prognosis and immune infiltration in the tumor microenvironment, suggesting its potential as a prognostic biomarker and therapeutic target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.